Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery
暂无分享,去创建一个
L. Cozzi | A. Fogliata | A. Chiti | M. Sollini | L. Antunovic | M. Kirienko | A. Rossi | E. Voulaz | L. Lozza
[1] Kujtim Latifi,et al. Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall‐cell lung cancer patients treated with stereotactic body radiotherapy , 2017, Medical physics.
[2] Carsten Brink,et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] Tong-fu Yu,et al. Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival , 2017, European Radiology.
[4] L Cozzi,et al. PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology , 2017, Scientific Reports.
[5] Philippe Lambin,et al. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures , 2017, The British journal of radiology.
[6] J. Fontaine,et al. Efficacy of lymph node dissection during robotic-assisted lobectomy for non-small cell lung cancer: retrospective review of 159 consecutive cases. , 2016, Journal of thoracic disease.
[7] A. D’Andrilli,et al. Lymph node dissection after pulmonary resection for lung cancer: a mini review. , 2016, Annals of translational medicine.
[8] Raymond H Mak,et al. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] V. Goh,et al. Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. , 2016, AJR. American journal of roentgenology.
[10] Vishwa Parekh,et al. Radiomics: a new application from established techniques , 2016, Expert review of precision medicine and drug development.
[11] Ronald Boellaard,et al. Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation , 2016, Molecular Imaging and Biology.
[12] D. Townsend,et al. Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET , 2015, The Journal of Nuclear Medicine.
[13] Irène Buvat,et al. Tumor Texture Analysis in PET: Where Do We Stand? , 2015, The Journal of Nuclear Medicine.
[14] Ji-Hoon Jung,et al. Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer , 2015, Clinical nuclear medicine.
[15] Benjamin Haibe-Kains,et al. Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer , 2015, Scientific Reports.
[16] Waranya Rattanavipapong,et al. Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development , 2015, PloS one.
[17] P. Marsden,et al. False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review , 2015, PloS one.
[18] P. Lambin,et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[20] Georg Schramm,et al. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC , 2014, BMC Cancer.
[21] Florent Tixier,et al. Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non–Small Cell Lung Cancer , 2014, The Journal of Nuclear Medicine.
[22] S Senan,et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[24] Fumihiro Tanaka,et al. Recurrence after surgery in patients with NSCLC. , 2014, Translational lung cancer research.
[25] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[26] J. Crowley,et al. The revised TNM staging system for lung cancer. , 2009, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
[27] Ping Yang,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[28] W. Rom,et al. Survival after surgery in stage IA and IB non-small cell lung cancer. , 2008, American journal of respiratory and critical care medicine.
[29] T. Waldmann,et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Brundage,et al. Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.
[31] Frank C. Detterbeck,et al. The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.
[32] Florent Tixier,et al. Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[33] M. Kris,et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. , 2014, The Lancet. Oncology.
[34] L. Leslie,et al. A decade of progress. , 1969, Minnesota medicine.